anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: chemistry; biochemistry. ^ SUBSTANCE: invention relates to biotechnology and can be used in various industries. The method involves the following. Initial material, e.g. cartilaginous tissue of fish, bird, shellfish or mammals is ground up. The ground initial material immersed in a 0.0025-0.05 n solution of an alkali metal salt. The obtained extract is centrifuged to separate the solid and oil phase. The obtained liquid phase is centrifuged to obtain a filtrate. The obtained filtrate is washed with distilled water which is 6 times more than the volume of the filtrate with subsequent separation and concentration of the obtained end product. ^ EFFECT: invention enables production of proteoglycan in unaltered undecomposed form in a short period of time. ^ 1 dwg, 10 ex
The present invention discloses a pharmaceutical composition of cephalexin, which comprises cephalexin, adhesive, edulcorant and flavoring agent, wherein, the mass percentage of cephalexin is 10% -50%. The mass percentage of adhesive is 10%-50%. The mass percentage of edulcorant is 5%-90%. The invention adopts the essence with flavor masking function for masking the special flavor in the pharmaceutical composition of cephalexin and improves the mouthfeel of medicine particle through adding edulcorant. The invention researches out the contents of optimal flavor masking essence and edulcorant through large number of experiments. The medicine particle of cephalexin prepared according to the formula of the invention has the advantages of no bad smell in medicine taking, fragrant and sweet taste for facilitating the medicine taking of patient.
This will be a 6-week, open label, bilaterally-controlled single center study involving 30 subjects age 13 and older with eczema. The primary objective of this clinical study is to determine whether occlusion of triamcinolone 0.1% cream (TAC) used to treat eczema with hydrogel patch improves its efficacy. A secondary objective is to determine whether eczema improves under occlusion with hydrogel patch alone. All subjects will have 3 target lesions of similar severity followed throughout the study. Patients will apply hydrogel patch alone to the first lesion, TAC 0.1% cream to the second lesion, and TAC 0.1% cream occluded by hydrogel patch to the third lesion. All treatments are twice a day for a maximum of 4 weeks or until lesions are cleared. The modified Eczema Area and Severity Index (EASI) score will be used to evaluate each lesion.
Background Psoriasis is a chronic, inflammatory, systemic disease with predominant manifestations in the skin and joints impairing patient's quality of life. A proportion of patients have frequent severe disease exacerbations requiring repeated systemic treatments. There is a scarcity of literature evaluating the role of systemic maintenance therapy in psoriasis patients in preventing such frequent disease flares. Objective To evaluate the efficacy and safety of weekend cyclosporine treatment (WCT) as maintenance therapy in moderate to severe chronic plaque psoriasis patients for the prevention of frequent disease exacerbations. Methods In this retrospective cohort study, 22 psoriasis patients with a history of frequent disease exacerbations (≥ 3 in the last 1 year) who were administered WCT (group A) were compared with the same number of matched patients (age and gender) not on WCT or any systemic maintenance therapy (group B). Results Four patients (18.2%) in group A had disease exacerbations which was significantly lower (p = 0.00, Fisher's exact test) as compared to 21 patients (95.5%) in group B during the study period. Also, patients in group A had significantly lower number of overall exacerbations [mean ± SD: 0.23 ± 0.53 vs 2.95 ± 1.43) p = 0.00, Mann-Whitney U test] as compared to group B. Four (9.1%) patients in group A encountered adverse effects (acneiform eruptions - two, mild gingival hyperplasia - one, myalgia - one) as compared to three (acneiform eruptions - two, headache - one) in group B (p = 1.00). Conclusion WCT significantly reduced the number of disease exacerbations and is a safe and effective mode of maintenance therapy in such subset of psoriasis patients.
This invention provides a composition containing beta-glucan, which is characterized in further improving the physiological activity of beta-1,3-1,6-glucan contained in the culture of Aureobasidium sp., and a constipation improver, an immune activator and a dermatological moisturizer using said composition. Said composition comprise a culture broth of Aureobasidium sp. containing beta-1,3-1,6-glucan and lactic acid bacteria. Such composition having beta-glucan can be used as the effective ingredient in a constipation improver, an immune activator or a dermatological moisturizer. The above bacteria of Aureobasidium sp. is preferably Aureobasidium pullulans M-1 (FERM BP-08615). Further, the above lactic acid bacteria is preferably Enterococcus faecalis, and the above lactic acid bacteria is more preferably the thermally sterilized one. In addition, the solid parts preferably contains 1 to 80 mass% of said culture based on the beta-1,3-1,6-glucan and 4 to 95 mass% of lactic acid bacteria.
The application provides a suicide risk prediction model generation method, which comprises the following steps: step 1: the psychological health questionnaire is used by an online platform to carry out questionnaire survey on primary and secondary schools in the city. Step 2: after questionnaires were retrieved, high risk factors affecting suicidal behavior were analyzed using binary logistic regression with depression, anxiety, gender, age, etc. as independent variables and high suicidal risk as dependent variables. And step 3: the suicide high risk is used as a prediction target, depression, anxiety, gender, age and the like are used as risk factors, a mathematical model of sample data is established by using an XGboost machine learning method, and effective prediction is carried out on suicide high risk teenagers. In addition, the performance of the XGboost model is compared with 7 different machine learning methods such as Gaussian naive Bayes, support vector machines, random forests and the like on the same data set, and the accuracy and the reliability of the XGboost model are further proved. According to the invention, data acquisition is simple and convenient, identification of the suicide possibility of teenagers is realized by using simple and understandable questionnaires and artificial intelligence technology, and powerful support is provided for preventing and intervening psychological crisis.
The present invention relates to devices including a protein matrix material and the methods of making and using such devices. More specifically the present invention relates to protein matrix devices that may be utilized for various medical applications including, but not limited to, current (magnetic and electric) released drug delivery devices for the controlled release of pharmacologically active agents, electromatrix devices (e.g. antennae, leads, chips, wires, etc), coatings for implantable medical devices (e.g. Micro-Electronics Minaturization Systems (MEMS), pacemakers, etc.) and imaging and diagnostic devices. Furthermore, the present invention relates to devices including a protein matrix made by forming a film comprising one ore more biocompatible protein materials and one or more biocompatible solvents. The film may also optionally include one or more pharmacologically active agents and/or one or more conductive materials. The film is then partially dried, rolled or otherwise shaped, and then compressed to form the desired protein matrix device. During the rolling or shaping of the film, one or more conductive materials, and/or one or more implantable devices may be placed into the film and thereby compressed to form a coating around the conductive materials, and/or implantable devices.
This is a randomized (study drug assigned by chance), exploratory, open-label (all involved people know the identity of the intervention) trial to evaluate the pharmacokinetics (PK), safety, tolerability and anti-HIV (anti Human Immunodeficiency Virus) activity of etravirine (ETR ) when given with atazanavir/ritonavir (ATV/rtv) and 1 nucleoside reverse transcriptase inhibitor (NRTI) in 46 treatment experienced HIV-1 infected patients. The trial will consist of : 4 weeks of Screening Period, 2 weeks Pre-Treatment Phase, 48-week Treatment Period, and a Final Visit followed by a 4-week Follow-up Period (only for patients not continuing treatment with ETR in another trial or program). Safety evaluations (AE reporting, labs, vital signs, etc.) will be monitored at each study visit. A PK substudy (included in the protocol, with optional participation) with tenofovir (TDF) added to the antiretroviral regimen for 7 days will be conducted in patients with \> 24 weeks of treatment with suppressed HIV-1 viral load. In Pre-Treatment Phase, all patients will receive ATV/rtv 300/100 mg once daily to be taken following a meal each morning + 2 NRTIs (dose as specified in the labels) for 14 days. In Treatment Phase, patients will receive ETR 200 mg twice daily in addition to ATV/rtv (300/100 mg or 400/100 mg) once daily with meals + 1 investigator-selected NRTI for 48 weeks. In substudy TDF 300 mg once daily will be added to the treatment regimen x 7 days.
Physical functioning can be increased in people with stroke by using a mobile health application. This study aimed to investigate the feasibility of a 10-week community-based program using the WalkWithMe (WWM) application in people with late sub-acute and chronic stroke in Benin. An interventional pilot study with mixed methods research design was used examining the application of an unsupervised individualized mobile Health (mHealth) instructed training program. Main outcome included the application usage, safety, adherence, perceived enjoyment, mHealth quality, patient experiences and pre-post efficacy measures. Nine adults, five males, median age of 60 years and time since stroke of 12 months participated in this study. For most participants adherence with the application was over 70%. However, some usability problems were observed due to incorrect understanding and use by participants and technical problems. The application was very fun, stimulating and enjoyable. Significant improvements were found with median (pre/post measures) of locomotors skill (1.4/3.4); impairments (38/40), Barthel Index (85/95), activity limitation (2.1/3.1), and quality of life (194/218). A trend towards significant improvement was found with 6 minutes walking test (181/220, p = 0.06). The WWM application is perceived as a potential approach to increase physical activity and functioning among people with stroke in Benin.
Frailty in cirrhosis or advanced chronic liver disease (ACLD) is a relevant prognostic factor. In the present study, we aimed to analyze potential biomarkers associated with frailty and its improvement in patients with ACLD. We analyzed the serum of outpatients with ACLD who participated in a previous study (Román, Hepatol Commun 2024) in which frailty was assessed using the liver frailty index (LFI), and patients who were frail or prefrail were randomized to a multifactorial intervention (home exercise, branched-chain amino acids, and probiotics) or control for 12 months. We determined a biomarker battery of inflammation, bacterial translocation, and liver damage in blood and urine and blood metabolomics by 1H-NMR. Thirty-seven patients were included. According to the LFI, 32 patients were frail or prefrail, and 5 were robust. At baseline, LFI correlated with LBP, sCD163, mtDNA, FGF-21, urinary NGAL, urinary claudin-3, and the metabolites mannose, ethanol, and isoleucine. During the study, patients in the intervention group showed an improvement in LFI and a decrease in CRP, LBP, sCD163, and ccK18 compared to the control group. Metabolomics showed a decrease in dimethyl sulfone and creatinine and an increase in malonate, ornithine, isoleucine, and valine in the intervention group. We conclude that frailty in patients with ACLD is associated with biomarkers of systemic inflammation, bacterial translocation, and liver damage, and alterations of amino acid and short-chain fatty acid metabolism.
The invention provides an MCM (micro-Chinese medicine) molecule penetration absorption treatment for the treatment of a lumbar vertebra disease, and the bed comprises a bed body. The bed body comprises a bed plate and a supporting column. The supporting column is vertically disposed at a side of the bed plate, and the bed plate is provided with a thermal conduction plate in an embedded manner. The thermal conduction plate is covered by traditional Chinese medicine compositions for the treatment of the lumbar vertebra disease. The bottom of the bed plate is provided with a water tank, and the bottom of the water tank is provided with a heater. The bed provided by the embodiment of the invention changes a conventional treatment mode, is good in treatment effect, and has no side effect.
PROBLEM TO BE SOLVED: To obtain a water dispersion composition which is stably dispersed in water especially in an acidic range and is provided with excellent functions as a suspension stabilizing agent, a emulsification stabilizing agent, a fat and oil substrate, etc., by including fine cellulose and chitosan. SOLUTION: The dry composition includes fine cellulose (appropriately, its average particle size is less than 4μm) and chitosan (appropriately, its deacetylation degree is more than 85% and viscosity at concn. 5% is less than 100 centipoise) and shows a stably dispersed state at the time of stirring in water. It is desirable that with respect to the component A, the component B is mixed by 5 to 40% by weight part. The component A is obtained by depolymerization-processing wood pulp by acid-hydrolysis, etc., to be the cellulose of an average degree of polymerization 30 to 375 and then wet-grinding it. In order to sufficiently disperse the component B in the composition, an acid component is desirably added to swell the component B.  It is desired that the acid component is added to make the number of mols of the hydrogen ion of the acid 10 to 500% with respect to the number of the mols of the amino group of the component B.
Participants in this group will not receive any mental health intervention during the study period. They will complete the PHQ-9 and GHQ-12 questionnaires at the start and end of the 3-month period to assess changes in emotional distress and depressive symptoms for comparison with the intervention group.
OBJECTIVE: To characterize seizure tracking patterns of people with focal epilepsy using electronic seizure diary entries, and to assess for risk factors associated with poor tracking.
METHODS: We analyzed electronic seizure diary data from 410 participants with newly diagnosed focal epilepsy in the Human Epilepsy Project 1 (HEP1). Each participant was expected to record data each day during the study, regardless of seizure occurrence. The primary outcome of this post-hoc analysis was whether each participant properly tracked a seizure diary entry each day during their study participation. Using finite mixture modeling, we grouped patient tracking trajectories into data-driven clusters. Once defined, we used multinomial modeling to test for independent risk factors of tracking group membership.
RESULTS: Using over up to three years of daily seizure diary data per subject, we found four distinct seizure tracking groups: consistent, frequent at study onset, occasional, and rare. Participants in the consistent tracking group tracked a median of 92% (interquartile range, IQR: 82%, 99%) of expected days, compared to 47% (IQR:34%, 60%) in the frequent at study onset group, 37% (IQR: 26%, 49%) in the occasional group, and 9% (IQR: 3%, 15%) in the rare group. In multivariable analysis, consistent trackers had lower rates of seizure days per tracked year during their study participation, compared to other groups.
SIGNIFICANCE: Future efforts need to focus on improving seizure diary tracking adherence to improve quality of outcome data, particularly in those with higher seizure burden. In addition, accounting for missing data when using seizure diary data as a primary outcome is important in research trials. If not properly accounted for, total seizure burden may be underestimated and biased, skewing results of clinical trials.
BACKGROUND: Recently, the incidence of missed miscarriage has gradually increased, and medical abortion is a common method to terminate a pregnancy. In the process of medical abortion, massive vaginal bleeding takes place, leading to emergency surgical haemostasis. Emergency surgery may produce infection and organ damage. Our study aimed to investigate the high-risk factors for massive haemorrhage during a medical abortion.
METHODS: A total of 1062 missed miscarriage patients who underwent medical abortion participated in this retrospective study. According to the amount of bleeding, the patients were divided into a massive haemorrhage group and a control group. By comparing the general conditions of the two groups, such as fertility history, uterine surgery history, uterine fibroids, etc., the high-risk factors for massive haemorrhage during medical abortion were identified.
RESULTS: Relative to the control group, the massive haemorrhage group exhibited a higher proportion of patients with a previous artificial abortion (51.9% vs. 38.1%, P = 0.001). Additionally, the massive haemorrhage group had a lower percentage of first-time pregnant women (32.1% vs. 40.4%) and a higher proportion of women with shorter pregnancy intervals (44.9% vs. 33.1%, P = 0.03). Furthermore, there were notable differences between the two groups regarding maximum fibroid size, the duration of amenorrhea, and gestational week (P < 0.05).
CONCLUSION: In this study, we determined that a history of artificial abortion and an amenorrhea duration of > 11 weeks represented high-risk factors for massive vaginal bleeding during medical abortion in missed miscarriage patients.
Patients were orally administrated with 50 mg puerarin tablet three times a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
The invention relates to the technical field of hospital information interaction, in particular to a hospital information interaction management system based on the Internet of things. The system comprises a patient information interaction module, a diagnosis and treatment support module, a perception interaction module, a medicine management module, a medical logistics automation module and an equipment management module. The patient information interaction module updates and manages patient data in real time through the Internet of things device. The diagnosis and treatment support module is combined with AI to analyze physiological parameters of the patient and dynamically adjust the treatment scheme. The perceived interaction module utilizes speech recognition and emotion analysis to improve service interaction. The medicine management module realizes automatic tracking and intelligent inventory management of medicines. The medical logistics automation module realizes resource optimization allocation through intelligent technology and robots. The equipment management module monitors the state of the equipment of the Internet of things, and ensures the efficient operation of the system. The invention can improve the efficiency and quality of medical service, optimize resource allocation and realize the intellectualization of hospital management through the cooperative work of a plurality of modules.
This study aims to compare the effects of a therapist-performed mobilization with movement (MWM) technique with those of a dynamic stretch with over pressure on active hip flexion range of motion (ROM) in those with active hip flexion ROM limitations.Those individuals from the University of South Carolina's Department of Physical Therapy (UofSC DPT) community who are interested in becoming study participants will be identified by means of announcements made in the Seminar in Physical Therapy course which is attended by all students, faculty, and staff of UofSC DPT each week. Interested individuals will be provided with Cathy Arnot's email address in order to schedule an evaluation session to determine whether or not they meet the study's inclusion and exclusion criteria. In addition, Sarah Cooper will attend a staff meeting at Vertex PT Specialists to make an announcement and provide the attendees with Cathy Arnot's email for inquiries. Participants will be assigned to either the MWM group or the dynamic stretch with over pressure group via blocked randomization for sex and age, with at least seventeen participants being placed into each group. The MWM group participants will receive a therapist-performed MWM technique and a prescription for a home exercise program (HEP) consisting of a dynamic stretch with over pressure to be performed once a day over the course of the following week. The dynamic stretch with over pressure group participants will receive only the prescription for the HEP consisting of the dynamic stretch with over pressure to be performed once a day over the following week. Measurements will be assessed at four time points: Immediately before the intervention, immediately after the intervention, 24 hours after the intervention, and one week after the intervention.
The instant disclosure generally relates to a multicomponent composition for coloring mammalian or synthetic substrate material and textiles, the composition comprising first and second components and optionally a third component. The composition comprises a silicone polymer or first and second silicone polymers and pigment microparticles. The silicone polymer or polymers comprise reactive organosiloxane monomer units having functional groups arranged as complementary reactive pairs or as a self-reactive functional group. The components may meld together on substrate material and textiles and especially on hair to form a highly remanent colored coating. The multicomponent composition formed and set  in situ  as a solid linked coating has a substantially permanent pigment lastingness and minimally alters the substrate material and textiles. A removal composition suitable for removing the formed coating comprises one or more of surfactant, solvent, acid, base, polymer, polyelectrolyte, salt sources of fluorine and ionic liquids. In particular, the removal composition comprises tetrabutylammonium fluoride.
The participant pool in this arm are from the MT10109L-002 lead-in study (NCT03785145), who received Placebo in period 1 and MT10109L Dose 2 in period 2. Eligible participants from this study continue receiving Dose 2 in the open-label MT10109L-004 study.
Ceftazidime-avibactam is a novel cephalosporin/B-lactamase inhibitor developed in the context of increasing resistance. This case reports the pharmacokinetics of ceftazidime-avibactam in a critically ill child under continuous renal replacement (CRRT) therapy for fluid overload. The patient was a 6-month-old female with sepsis due to bloodstream infection to Stenotrophomonas maltophilia following stem cell transplantation for severe combined immunodeficiency. CRRT was started on Day 2. Concentrations have been monitored using liquid chromatography-tandem mass spectrometry. Treatment was given every 8 h with a 2 h infusion of 30-7,5 mg/kg and did not reach pharmacokinetic/pharmacodynamic targets. Total clearance was respectively 1.7 and 3.02 L/h, with CRRT clearance respectively 28.8%-60% for ceftazidime and 14%-33% for avibactam. Those clearances are higher than reported in adult literature leading to a risk of treatment failure and emerging resistance. This supports the benefit of monitoring antimicrobial therapy under CRRT and the necessity to assess higher dosing or continuous infusion of ceftazidime-avibactam.